Navigation auf


UZH Innovation Hub

Biotech company opts for UZH spin-off Oncobit

Founded in 2018 as a UZH spin-off, Oncobit announces partnership with Immunocore to advance therapy response analysis in clinical trials. 

Immunocore Holdings plc is a biotech company pioneering the development and delivery of novel immunomodulatory therapeutics to radically improve treatment outcomes for patients with cancer, infectious diseases and autoimmune disorders. This collaboration aims to improve the use and understanding of circulating tumor DNA (ctDNA) analysis as a reliable real-time marker of treatment response in clinical trials.

Oncobit press release

From Lab to Market – In the last year, eight new spin-offs were created at the University of Zurich to bring research-based ideas to market readiness.